Vanguard's VXUS vs. Schwab's SCHE: How These International ETFs Compare on Risk, Returns, and Diversification

VXUS offers broader international diversification than SCHE, with a lower expense ratio of 0.05% vs. 0.07%, a higher dividend yield of 2.76% vs. 2.67%, and stronger 5-year performance ($1,504 vs. $1,304 on a $1,000 investment). SCHE is more concentrated in emerging markets, with 2,213 holdings, a 35.73% 5-year max drawdown, and heavier technology exposure at 30% versus VXUS’s 18%. The piece is comparative and informational, with no new catalyst likely to materially move either ETF.

Analysis

The real takeaway is that the market is still paying up for emerging-market beta, but the cleaner expression of that view is not the narrower EM vehicle. VXUS gives you the same EM cyclical upside with a built-in stabilizer from developed ex-US exposure, which matters if rates stay sticky and USD funding conditions tighten again. In that regime, the higher-beta EM-only basket is more likely to underperform on drawdowns than to deliver enough incremental upside to justify the extra volatility.

Second-order, the concentration in tech-heavy EM exposure means SCHE is effectively a levered proxy for a handful of supply-chain and AI hardware beneficiaries rather than a broad EM consumer recovery. That creates hidden single-factor risk: if semiconductor capex rolls over or Taiwan-related geopolitical risk reprices, SCHE can gap down faster than the headline EM complex. VXUS is less exciting, but its broader sector balance should make it the better risk-adjusted allocator if you’re trying to harvest international exposure without making a binary growth bet.

From a factor perspective, the income spread is too small to matter structurally, so the real differentiator is path dependency. SCHE’s deeper historical drawdown suggests it will be more sensitive to the next bout of real-rate volatility over the next 3–6 months, while VXUS should be more resilient if global earnings breadth broadens beyond tech. The article’s implied consensus is that emerging markets are where the growth is; what’s missing is that broad ex-US exposure may actually be the better way to own that growth while reducing left-tail risk.

The named holdings are where the debate really sits: TSM and ASML look like higher-quality long-duration compounders, while BABA remains a policy/risk-premium trade rather than a pure fundamentals story. If the AI supply chain stays intact, both funds benefit, but SCHE has more downside if that trade unwinds because its portfolio is less diversified and more narrative-dependent.

Key Decisions for Investors

• Long VXUS / short SCHE as a 3-6 month relative-value trade: expression of 'EM participation without EM-specific tail risk'; target modest alpha with lower drawdown than outright EM exposure.
• If building strategic international exposure, prefer VXUS on pullbacks rather than chasing SCHE strength; use SCHE only as a tactical satellite for a 6-12 month EM rebound window.
• For higher-conviction AI supply-chain exposure, own TSM and ASML directly instead of relying on SCHE; this removes country/sector dilution and improves risk/reward if semicap capex remains firm over the next 12 months.
• Avoid using SCHE as an income substitute: the yield pickup versus VXUS is de minimis, while the volatility and max-drawdown penalty is materially worse.
• If USD weakens and global PMI data re-accelerates, add SCHE vs VXUS on a 1-2 month lagged basis; that macro setup is the cleanest catalyst for SCHE outperformance.